ALAMEDA, Calif.--(BUSINESS WIRE)--Oct. 3, 2017--
BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology
company focused on developing and commercializing products addressing
degenerative diseases, today announced that Jim Knight, SVP, Head of
Corporate Development, will present at the Cell & Gene Therapy Meeting
on the Mesa. Mr. Knight will provide an overview of the Company in his
presentation on Thursday, October 5, 2017 at 4:45 pm PT/7:45 pm ET.
About BioTime, Inc.
BioTime is a late stage clinical biotechnology company focused on
developing and commercializing products addressing degenerative
diseases. The Company’s current clinical programs are targeting three
primary sectors, aesthetics, ophthalmology and cell/drug delivery. Its
clinical programs are based on two platform technologies: pluripotent
cells, which can become any type of cell in the human body, and
cell/drug delivery. Renevia®, a cell delivery product, met its primary
endpoint in an EU pivotal trial for the treatment of facial lipoatrophy
in HIV patients earlier this year. Submission for approval of Renevia®
is expected later this year, with an anticipated commercial launch in
2018. OpRegen®, a retinal pigment epithelium transplant therapy, is in a
Phase I/IIa multicenter trial for the treatment of dry age-related
macular degeneration, the leading cause of blindness in developing
countries. BioTime also has significant equity holdings in two publicly
traded companies, Asterias Biotherapeutics, Inc. (NYSE American: AST)
and OncoCyte Corporation (NYSE American: OCX), and one private company,
AgeX Therapeutics, Inc.
BioTime common stock is traded on the NYSE American and TASE under the
symbol BTX. For more information, please visit www.biotimeinc.com or
connect with the company on Twitter, LinkedIn, Facebook, YouTube,
To receive ongoing BioTime corporate communications, please click on the
following link to join the Company’s email alert list: http://news.biotimeinc.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171003005571/en/
Source: BioTime, Inc.
David Nakasone, 510-871-4188
JQA Partners, Inc.
Jules Abraham, 917-885-7378